Lipid and inflammatory markers for the prediction of coronary artery disease: A multi-marker approach

Clinical Biochemistry

Volumn 40, Issue 13-14, 2007, Pages 1000-1006

  Bogavac Stanojević, Nataša ^a   Jelić Ivanović, Zorana ^a   Spasojević Kalimanovska, Vesna ^a   Spasić, Slavica ^a   Kalimanovska Oštrić, Dimitra ^b  

^a Department of Physical Chemistry   (Yugoslavia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Apolipoprotein (a); Inflammatory markers; Lipoprotein (a); Logistic regression model; Receiver operating characteristic curve

Indexed keywords

APOLIPOPROTEIN; C REACTIVE PROTEIN; DODECYL SULFATE SODIUM; FIBRINOGEN; LIPID; LIPOPROTEIN;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; FIBRINOGEN BLOOD LEVEL; GEL ELECTROPHORESIS; HUMAN; IMMUNOCHEMISTRY; LABORATORY TEST; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PARAMETER; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ROC CURVE; SEX RATIO; SMOKING;

ADULT; APOLIPOPROTEINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CONFIDENCE INTERVALS; CORONARY ARTERIOSCLEROSIS; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; LIPIDS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; ROC CURVE;

EID: 34548152793     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.05.012     Document Type: Article

References (35)

1. Causes of deaths. In: D. Vukomirovic, editor. Statistical Yearbook of Serbia 2005. Belgrade, Serbia, SCG: Statistical Office of the Republic of Serbia; 2005. p. 90.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
3. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J. 24 (2003) 1601-1610
4. Yang Q., Khoury M.J., Botto L., Friedman J.M., and Flanders W.D. Improving the prediction of complex disease by testing for multiple disease-susceptibility genes. Am. J. Hum. Genet. 72 (2003) 636-649
5. Genest Jr. J., McNamara J.R., Ordovas J.M., et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J. Am. Coll. Cardiol. 19 (1992) 792-802
6. Carmena R., Duriez P., and Fruchart J.-C. Atherogenic lipoprotein particles in atherosclerosis. Circulation 109 suppl 1 (2004) III-2-III-7
7. Ridker P.M., Hennekens C.H., and Stampfer M.J. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270 (1993) 2195-2199
8. Cantin B., Gagnon F., Moorjani S., DesPres J.P., et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J. Am. Coll. Cardiol. 31 (1998) 519-525
9. Genest J., Frohlich J., Fodor G., and McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 169 (2003) 921-924
10. Enas E.A., Dhawan J., and Petkar S. Coronary artery disease in Asian Indians: lessons learnt and the role of lipoprotein (a). Indian Heart J. 49 (1997) 25-34
11. Das B., Daga M.K., and Gupta S.K. Lipid pentad index: a novel bioindex for evaluation of lipid risk factors for atherosclerosis in young adolescents and children of premature coronary artery disease patients in India. Clin. Biochem. 40 (2007) 18-24
12. Stern M.P., Fatehi P., Williams K., and Haffner S.M. Predicting future cardiovascular disease: do we need the oral glucose tolerance test?. Diabetes Care 25 (2002) 1851-1856
13. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
14. Kamboh M.I., Ferrel R.E., and Kottke B.A. Expressed hypervariable polymorphism of apolipoprotein (a). Am. J. Hum. Genet. 49 (1991) 1063-1074
15. Rifai N., Ma J., Sacks F.M., et al. Apolipoprotein(a) size and lipoprotein (a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. Clin. Chem. 50 (2004) 1364-1371
16. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
17. Hanley J.A., and McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 (1983) 839-843
18. Bland J.M., and Altman D.G. Transformations, means and confidence intervals. BMJ 312 (1996) 1079
19. Hosmer D.W., and Lemeshow S. Assessing the fit of the model. Applied Logistic Regression (2000), John Wiley and sons, NY 160-164
20. Ridker P.M., Hennekens C.H., Buring J.E., et al. C reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 (2000) 836-843
21. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-I and B, and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) study. Circulation 104 (2001) 1108-1113
22. Meisinger C., Loewel H., Mraz W., and Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur. Heart J. 26 (2005) 271-278
23. Zweig M.H., Broste S.K., and Reinhart R.A. Roc curve analysis: an example showing the relationships among serum lipid and apolipoprotein concentrations in identifying patients with coronary artery disease. Clin. Chem. 38 (1992) 1425-1428
24. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
25. Singleton J.R., Smith A.G., Russell J.W., and Feldman E.L. Microvascular complications of impaired glucose tolerance. Diabetes 52 (2003) 2867-2873
26. Wel M., Gaskill S.P., Haffner S.M., and Stern M.P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: the San Antonio Heart Study. Diabetes Care 21 (1998) 1167-1172
27. Rewers M., Shetterly S.M., Baxter J., Marshall J.A., and Hamman R.F. Prevalence of coronary heart disease in subjects with normal and impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a biethnic Colorado population: the San Luis Valley Diabetes Study. Am. J. Epidemiol. 135 (1992) 1321-1330
28. Blake D.R., Meigs J.B., Muller D.C., Najjar S.S., Andres R., and Nathan D.M. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors. Results from the Baltimore Longitudinal Study on Aging. Diabetes 53 (2004) 2095-2100
29. Goetze J.P., Christoffersen C., Perko M., et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 17 (2003) 1105-1107
30. Groenning B.A., Nilsson J.C., Sondergaard L., et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am. Heart J. 143 (2002) 923-929
31. Cook N.R., Buring J.E., and Ridker P.M. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann. Intern. Med. 145 (2006) 21-29
32. Ridker P.M. Evaluating novel cardiovascular risk factors: can we better predict heart attacks?. Ann. Intern. Med. 130 (1999) 933-937
33. Bittner V., Hardison R., Kelsey S.F., Weiner B.H., Jacobs A.K., and Sopko G. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 106 (2002) 2537-2542
34. Cui Y., Blumenthal R.S., and Flaws J.A. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 161 (2001) 1413-1419
35. Farwell W.R., Sesso H.D., Buring J.E., and Gaziano J.M. Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction. Am. J. Cardiol. 96 (2005) 1129-1134